NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied	Prodromal AD
Date of first enrollment	13/11/2016
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Solanezumab INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for Investigational material : Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 55age old
Age maximum	<= 85age old
Gender	Both
Include criteria	- Is aged 55-85 years - Has a diagnosis of a clinical syndrome of cognitive impairment consistent with prodromal AD per IWG diagnostic criteria or MCI due to AD per NIA-AA diagnostic criteria - Has a PET scan or CSF result with the presence of amyloid pathology
Exclude criteria